Stay updated on Amgen Press Releases
Sign up to get notified when there's something new on the Amgen Press Releases page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2Fda52pxSoeBT8dIYkEzv2psJe9XE.uncropped.jpg&w=3840&q=75)
Latest updates to the Amgen Press Releases page
- Check2 days agoChange DetectedAmgen has announced several significant updates, including the availability of Otezla® for pediatric plaque psoriasis, upcoming presentations at major healthcare conferences, and the approval of Blincyto® for a specific type of leukemia.SummaryDifference100%
- Check9 days agoNo Change Detected
- Check17 days agoChange DetectedAmgen has made several significant announcements, including the approval of Blincyto® for B-ALL and the first quarter 2024 financial results, while notable deletions include the second quarter 2024 financial results and the announcement of the third quarter dividend.SummaryDifference100%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedAmgen has reported its second quarter 2024 financial results and announced a third quarter dividend, along with a webcast for the financial results.SummaryDifference38%
- Check38 days agoChange DetectedIn June 2024, the FDA approved Blincyto® for treating CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia, while Amgen announced positive Phase 3 trial results for Uplizna® and plans to present at several major healthcare conferences.SummaryDifference100%
- Check41 days agoChange DetectedAmgen has made significant advancements in oncology and rheumatology, including the FDA approval of Blincyto for B-ALL and Imdelltra for small cell lung cancer, alongside positive trial results for Uplizna in IgG4-RD.SummaryDifference100%
- Check42 days agoChange DetectedIn June 2024, the FDA approved Blincyto® for treating CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia, while Amgen announced positive results for Uplizna® in treating IgG4-related disease and plans to present innovative rheumatology research at EULAR 2024.SummaryDifference100%
Stay in the know with updates to Amgen Press Releases
Enter your email address, and we'll notify you when there's something new on the Amgen Press Releases page.